Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment

During glioblastoma treatment, the pharmaceutical monoclonal antibody to vascular endothelial growth factor A, bevacizumab, has improved the quality of life and delayed progression for several months, but has not (or only marginally) prolonged overall survival. In 2017, several dramatic research pap...

Descripción completa

Detalles Bibliográficos
Autor principal: Kast, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Concept Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313620/
https://www.ncbi.nlm.nih.gov/pubmed/30274295
http://dx.doi.org/10.3390/medsci6040084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313620/
https://www.ncbi.nlm.nih.gov/pubmed/30274295
http://dx.doi.org/10.3390/medsci6040084

Ejemplares similares